Projection of the impact of biomarker technology on medical diagnostics: Special focus on proteins

Improvement of the resolution of global scale detection for all molecular classes (nucleic acids, proteins, metabolites) propels the revolution of molecular diagnostics. The new molecular profiling technologies are driving the paradigm shift of medicine, and expected to result in continued increase of life expectancy in the western world. Challenges include technical matters, information storage, dissemination and access as well as financial and reimbursement constrains. An overview will be given in order to attempt to define the paradigm shift and to highlight some of the obvious challenges and barriers. Finally, the field of proteomics will be reviewed with special focus on technical limitations of global protein profiling technologies and their potential contribution to early disease diagnosis.

Biography

Laszlo Takacs is the CEO/CSO of Biosystems International. He funded Biosystems International in France and Hungary. Prior to Biosystems, he worked at Pfizer and Amgen in various management roles in biotech and drug R&D and translational medicine. Before his industrial experience, he was the Head of the Special Unit of NIAAA, National Institute of Health. He continues academic activities by teaching Medical Genome Biology at the University of Debrecen in Hungary. He holds an MD degree in General Medicine and a PhD in Molecular Sciences from Semmelweis University and the Academy of Sciences in Hungary.

laszlo.takacs@biosys-intl.com